Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sildenafil
Drug ID BADD_D02018
Description In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment for angina - or chest pain associated with inadequate blood flow to the heart - before being serendipitously indicated for treating erectile dysfunction in the late 1980s [A175732]. Nevertheless, it is because of this mechanism that sildenafil is also indicated for treating pulmonary arterial hypertension but is also additionally notorious for interacting with various anti-anginal or anti-hypertensive agents to develop potentially rapid, excessive, and/or fatal hypotensive crises [A175579, A175582, A175654]. Regardless, sildenafil, among a variety of other similar or related PDE5 inhibitors, has become a common and effective treatment for erectile dysfunction and since its formal approval for medical use in the public in 1998 [A175732], continues to see millions of prescriptions written for it internationally. Although the medication has historically been most popularly recognized as Pfizer's brand name Viagra, sildenafil is currently available generically and even as a non-prescription over the counter medication in some countries [L5656].
Indications and Usage For the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH).
Marketing Status Prescription; Discontinued
ATC Code G04BE03
DrugBank ID DB00203
KEGG ID D08514
MeSH ID D000068677
PubChem ID 135398744
TTD Drug ID D0Z7ZM
NDC Product Code 17856-8100; 50268-717; 52817-340; 71335-1028; 45865-833; 70518-1216; 71205-473; 60219-1751; 0378-1658; 71610-256; 60687-416; 61919-826; 82647-211; 71335-1649; 50436-0776; 68001-176; 43063-676; 70748-132; 72789-103; 72789-098; 82647-210; 50436-1210; 31722-965; 42291-747; 72888-016; 27241-175; 59762-0033; 70748-133; 65162-351; 50090-5906; 33342-121; 70518-1844; 68071-2552; 46144-320; 31722-711; 63187-789; 43063-940; 31722-967; 50090-5415; 53002-1719; 68071-4854; 50090-3493; 52817-341; 71335-1437; 13668-188; 69543-419; 52817-295; 63187-813; 68071-4617; 31722-966; 68071-2608; 0378-1660; 71335-1088; 70518-2128; 68788-7680; 72865-105; 71335-0288; 69238-1574; 50090-5039; 65862-691; 76420-061; 71205-623; 65862-690; 0093-5343; 50090-5325; 31722-776; 68071-2566; 27241-067; 72888-017; 72189-069; 50090-5235; 68071-2537; 0378-1659; 70859-015; 68071-4517; 71205-267; 53002-2719; 71205-305; 0093-5342; 50090-4646; 72865-103; 63629-8129; 50090-1766; 52817-342; 68071-4744; 55700-677; 63629-5029; 71205-509; 27241-069; 31722-710; 43063-941; 43063-982; 63739-072; 71335-1005; 72888-015; 50090-5802; 71205-220; 0093-5341; 68788-7879; 71335-1963; 27241-124; 71610-271; 71610-237; 50436-0034; 68071-2213; 42291-748; 13668-186; 70518-1641; 68788-7974; 65862-689; 31722-709; 0093-5517; 13668-187; 71205-088; 71335-0969; 71335-1777; 50090-4644; 72888-018; 71335-1638; 68071-2217; 72865-101; 68788-7775; 43063-668; 72865-102; 68001-363; 70748-131; 63629-7833; 68071-5115; 65862-688; 68071-4674; 68071-4599; 61919-755; 68071-2072; 68071-2602; 71205-542; 82647-212; 72189-298; 0591-4050; 60219-1753; 27241-068; 50090-5236; 59762-2058; 42291-746; 71205-231; 63187-619; 71205-498; 70934-903; 60219-1752; 68071-5251
Synonyms Sildenafil Citrate | Citrate, Sildenafil | 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate | NCX-911 | NCX 911 | NCX911 | Revatio | Sildenafil | UK 92480-10 | UK 92480 10 | UK 9248010 | UK-92,480-10 | UK 92,480 10 | Homosildenafil | Hydroxyhomosildenafil | Viagra | Acetildenafil | Sildenafil Lactate | Lactate, Sildenafil | Sildenafil Nitrate | Nitrate, Sildenafil | Desmethyl Sildenafil | Sildenafil, Desmethyl | Desmethylsildenafil
Chemical Information
Molecular Formula C22H30N6O4S
CAS Registry Number 139755-83-2
SMILES CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood glucose increased13.02.02.002--Not Available
Blood pressure abnormal13.14.03.0010.000554%Not Available
Blood pressure decreased13.14.03.0020.006091%Not Available
Blood pressure increased13.14.03.005--Not Available
Blood pressure systolic decreased13.14.03.0070.000554%Not Available
Blood testosterone decreased13.10.05.0040.001661%Not Available
Blood urea increased13.13.01.0060.000831%Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Breast enlargement21.05.04.001--Not Available
Bronchiectasis22.03.02.0050.000554%Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchopulmonary aspergillosis22.07.08.001; 11.03.01.0020.000217%Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.000831%
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac arrest02.03.04.0010.001661%
Cardiac failure02.05.01.0010.003394%
Cardiac failure acute02.05.01.0050.000144%Not Available
Cardiac failure congestive02.05.01.0020.008859%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000722%Not Available
Cardiogenic shock02.05.01.003; 24.06.02.0060.000433%Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Carotid artery stenosis24.04.06.001; 17.08.02.0010.000554%Not Available
Cataract06.06.01.0010.002492%
Cellulitis23.09.01.001; 11.02.01.0010.002215%Not Available
Cerebral haemorrhage17.08.01.003; 24.07.04.0010.001083%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 22 Pages